Christian Templin.

Cammann, Annahita Sarcon, M.D., Verena Geyer, Catharina A. Neumann, Burkhardt Seifert, Ph.D., Jens Hellermann, M.D., Moritz Schwyzer, M.D., Katharina Eisenhardt, M.D., Josef Jenewein, M.D., Jennifer Franke, M.D., Hugo A. Katus, M.D., Christof Burgdorf, M.D., Heribert Schunkert, M.D., Christian Moeller, M.D., Holger Thiele, M.D., Johann Bauersachs, M.D.D., Heinz-Peter Schultheiss, M.D., Charles A. Laney, M.D., Lawrence Rajan, M.D., Guido Michels, M.D., Roman Pfister, M.D., Christian Ukena, M.D.D., Raimund Erbel, M.D., Alessandro Cuneo, M.D., Karl-Heinz Kuck, M.D., Claudius Jacobshagen, M.D., Gerd Hasenfuss, M.D., Mahir Karakas, M.D., Wolfgang Koenig, M.D., Wolfgang Rottbauer, M.D., Samir M. Said, M.D., Ruediger C. Braun-Dullaeus, M.D., Florim Cuculi, M.D., Adrian Banning, M.D., Thomas A.S5 and S6 in the Supplementary Appendix).7 vs. 15.2 months; hazard ratio, 0.39; 95 percent CI, 0.31 to 0.49; P<0.001) . The robustness of the outcomes for progression-free of charge survival was confirmed by numerous prespecified analyses .41; 95 percent CI, 0.23 to 0.74; P=0.002) ; the prices of death had been 9 percent and 20 percent, respectively.66; 95 percent CI, 0.39 to at least one 1.11; P=0.11) ; the rates of death were 15 percent and 20 percent, respectively.66; 95 percent CI, 0.41 to 1 1.06; P=0.08) ; the prices of death were 8 percent and 12 percent, respectively. Overall survival medians were not reached. Most enrolled individuals were over the age of 70 years of age and acquired clinically meaningful health problems furthermore to CLL.